Becton Dickinson and Co

BDX remains in a Stage 2 advancing phase with a confirmed Momentum Breakout and rising EMAs reinforcing a medium-term bullish bias. However, price is extended above the EMA band and in extreme overbought territory, so execution readiness is limited. We will stalk for pullbacks into rising EMA support or the prior breakout zone for selective entries.

• ↑Maintains 3.6% dividend yield, returning $2.3B to shareholders in H1
• ↑Q2 revenue rose 2.6% YoY to $4.7B, led by double-digit biologics growth
• ↓Profitability and growth factors are weak, raising earnings sustainability concerns